- Home
- STRO vs CMPS Comparison
STRO vs CMPS Comparison
Compare STRO & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CMPS
- Stock Information
- Founded
- STRO 2003
- CMPS 2020
- Country
- STRO United States
- CMPS United Kingdom
- Employees
- STRO N/A
- CMPS N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- CMPS Health Care
- Exchange
- STRO Nasdaq
- CMPS Nasdaq
- Market Cap
- STRO 77.7M
- CMPS 364.9M
- IPO Year
- STRO 2018
- CMPS 2020
- Fundamental
- Price
- STRO $0.76
- CMPS $3.38
- Analyst Decision
- STRO Hold
- CMPS Strong Buy
- Analyst Count
- STRO 7
- CMPS 7
- Target Price
- STRO $3.97
- CMPS $17.83
- AVG Volume (30 Days)
- STRO 1.4M
- CMPS 5.0M
- Earning Date
- STRO 08-12-2025
- CMPS 07-31-2025
- Dividend Yield
- STRO N/A
- CMPS N/A
- EPS Growth
- STRO N/A
- CMPS N/A
- EPS
- STRO N/A
- CMPS N/A
- Revenue
- STRO $66,434,000.00
- CMPS N/A
- Revenue This Year
- STRO N/A
- CMPS N/A
- Revenue Next Year
- STRO N/A
- CMPS N/A
- P/E Ratio
- STRO N/A
- CMPS N/A
- Revenue Growth
- STRO N/A
- CMPS N/A
- 52 Week Low
- STRO $0.52
- CMPS $2.25
- 52 Week High
- STRO $5.17
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- STRO 44.98
- CMPS 45.23
- Support Level
- STRO $0.67
- CMPS $2.25
- Resistance Level
- STRO $0.87
- CMPS $2.82
- Average True Range (ATR)
- STRO 0.08
- CMPS 0.38
- MACD
- STRO -0.01
- CMPS -0.11
- Stochastic Oscillator
- STRO 34.81
- CMPS 38.97
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.